Compounds

A pharmaceutical composition comprising:

• a pharmaceutically acceptable carrier and/or excipient;
• and
• a compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:
• wherein:
• Y is selected from hydrogen, hydroxyl, —NH2, —NH—C1-4-alkyl, —NH-halo-C1-4-alkyl, and —C1-4-alkoxy;
• Z is selected from hydrogen, halogen, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CONH2, —SO2NH2, —NH2, —NHC1-4-alkyl, and —NHhalo-C1-4-alkyl;
• R1 is a phenyl ring being optionally substituted with one or more substituents selected from halogen, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, and —NR6S(O)2R5,
• R4A, R4B, R5, and R6 are each independently selected from hydrogen, C1-4-alkyl and halo-C1-4-alkyl;
• W is a pyridyl ring being optionally substituted with one or more substituents selected from halogen, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR7AR7B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR7AR7B, —C(O)NR7AR7B, —C(O)R5, —C(O)OR5, —SO2R5, —SO2R7AR7B and —NR6S(O)2R5;
• R7A and R7B are independently hydrogen, C1-4-alkyl, or halo-C1-4-alkyl;
• V is selected from a bond, —O—, —N(R6)—, —(C═O)—, —CONR6—, —NR6C(O)—, and —C1-4-alkylene-, wherein the C1-4-alkylene group is optionally substituted by halogen, and wherein any one of the carbon atoms of the C1-4-alkylene group may be replaced by —O— or —N(R6)—;
• and
• R3 is a cyclobutyl ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, —SO2R5, —SO2R4AR4B and —NR6S(O)2R5.